Stock IRWD IRONWOOD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
6.54 USD +2.99% Intraday chart for Ironwood Pharmaceuticals, Inc. -3.96% -42.83%
Jun. 10 Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing MT
May. 22 Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing
MT
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BU
Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing
MT
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure
AQ
Ironwood Pharmaceuticals : Late-Breaker Oral Presentation at Digestive Disease Week®
PU
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BU
Ironwood Pharmaceuticals, Inc. Presents Late-Breaking Data During the 2024 Digestive Disease Week Meeting from Its Pivotal Phase III Clinical Trial, STARS
CI
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading
MT
Sector Update: Health Care
MT
Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut
MT
Transcript : Ironwood Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
Ironwood Pharmaceuticals : 1Q 2024 Investor Update
PU
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $405M - $425M
MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q1 Revenue $74.9M
MT
Ironwood: Q1 Earnings Snapshot
AQ
Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024
CI
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
BU
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IRWD Stock
  4. News Ironwood Pharmaceuticals, Inc.